Tumor inflammation-associated neurotoxicity

Area of Science:

• Neuro-oncology
• Immunotherapy
• Cellular Therapy

Background:

• Cancer immunotherapies, including CAR T-cell therapy, present unique toxicity profiles.
• Established grading scales for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) improve safety in B cell malignancies.
• A distinct neurotoxicity syndrome has been observed in patients with central nervous system (CNS) tumors treated with cell therapies.

Purpose of the Study:

• To define and characterize a novel toxicity syndrome in CNS tumor immunotherapy, termed tumor inflammation-associated neurotoxicity (TIAN).
• To propose a standardized grading scale and management strategies for TIAN.
• To enhance the safe administration of cell therapies and other immunotherapies for CNS tumors.

Main Methods:

• Observational analysis of patients treated with cell therapies for CNS tumors.
• Definition and conceptualization of the TIAN syndrome, differentiating it from CRS and ICANS.
• Development of a proposed grading scale and discussion of potential management approaches for TIAN.

Main Results:

• Identification of a distinct neurotoxicity syndrome, TIAN, in patients with CNS tumors undergoing immunotherapy.
• TIAN encompasses concepts like 'pseudoprogression' and is broader than inflammation-induced edema.
• TIAN is relevant to both cellular therapies and other immunotherapies targeting CNS tumors.

Conclusions:

• TIAN represents a significant toxicity syndrome in CNS tumor immunotherapy.
• Standardized grading and management of TIAN are crucial for improving patient safety.
• The proposed framework aims to standardize reporting and management of TIAN for better clinical outcomes.